期刊文献+

HPLC法测定一种吡啶酮类医药中间体中5种杂质含量

Determination of five impurities in one kinds of pharmaceutical intermediate pyridinone by HPLC
下载PDF
导出
摘要 目的建立1-(4-氨基苯基)-5,6-二氢-3-(4-吗啉基)-2(1H)-吡啶酮(以下简称SM1)中5种杂质的分析方法。方法采用HPLC方法,色谱柱:Waters SunFire C_(18)(150mm×4.6mm,3.5μm);流动相A:0.03mol·^(-1)乙酸铵缓冲液-甲醇(75∶25),流动相B:0.03mol·^(-1)乙酸铵缓冲液-甲醇(25∶75),线性梯度洗脱;柱温35℃;检测波长320nm。结果建立了SM1中5种杂质的分析方法,5种成分的线性关系良好,平均回收率为100.4%~104.5%。结论所建立的HPLC法专属性强、精密度好、准确度高,可以作为SM1中5种杂质的测定方法。 OBJECTIVE The method was established to determine five impurities in 1-(4-aminophenyl)-5,6-dihydro-3-(4-morpholinyl)-2(1H)-pyridinone(Hereinafter referred to as SM1).METHODS HPLC method was applied,the separation was performed on a Waters SunFire C_(18) column(150mm×4.6mm,3.5μm)by liner gradient elution using 0.03mol·L^(-1)ammonium acetate solution-methanol(75∶25)as mobile phase A,0.03mol·L^(-1)ammonium acetate solution-methanol(25∶75)as mobile phase B,the column temperature was set at 35℃,and the detected wavelength was set at 320nm.RESULTS The method was established to determine five impurities in SM1,which had good linear relationship,and the average recoveries were between 100.4%to 104.5%.CONCLUSION The established method has strong specificity,good precision and high accuracy,which can be used for simultaneous determination of impurities in SM1.
作者 万国盛 兰公剑 王恩 陈栩 林萍 徐丹 WAN Guo-sheng;LAN Gong-jian;WANG En;CHEN Xu;LIN Ping;XU Dan(Nanjing Chia-Tai Tianqing Pharmaceutical Co.,Ltd.,Nanjing 210046,China)
出处 《化学工程师》 CAS 2022年第2期28-31,共4页 Chemical Engineer
关键词 1-(4-氨基苯基)-5 6-二氢-3-(4-吗啉基)-2(1H)-吡啶酮 高效液相色谱法 杂质测定 1-(4-aminophenyl)-5,6-dihydro-3-(4-morpholinyl)-2(1H)-pyridinone HPLC impurities determination
  • 相关文献

参考文献3

二级参考文献24

  • 1ICH Q3A (R2), Impurities in New Drug Substances[ EB/OL]. (2006 - 10-25). [2014 -03 -31]. http://www, ich. org/ LOB/media/MEDIA422. pdf.
  • 2ICH Q3B (R2) Impurities in New Drug Substances [ EB/OL]. (2006 -06-02). [2014 -03 -31]. http://www, ich. org/ LOB/media/MEDIA421. pdf.
  • 3ICH Q3C ( R3 ) Impurities: Guideline for Residual Solvents [EB/OL]. (2005-11). [2014 -03 -31]. http://www, ieh. org/LOB/media/MEDIA423, pdf.
  • 4EMEA. Guideline on the limits of Genotoxic hnpurities [ EB/OL]. (2006 -06 - 28). [2014 -03 -31]. http://www. emea. europa, eu/pdfs/human/swp/519902en, pdf.
  • 5EMEA. Questions & Answers on the CHMP Guideline on the Limits of Genotoxic Impurities, Revision 1 [ S]. (2008 - 06 -26). [2014 -03 -31]. http://www, emea. europa, eu/pdfs/ human/swp/43199407en, pdf.
  • 6FDA. Guidance for Industry Genotoxic and Carcinogenic Impuri- ties in Drug Substances and Products: Recommended Approaches [S]. (2008-11). [2014 -03 -31]. http:// www. fda. gov/ downloads/drugs/guidance complianceregulat-ory information/guidances/ucm079235, pdf.
  • 7ICH. Assessment And Control Of DNA Reactive (Mutagenic) Im- purities In Pharmaceuticals To Limit Potential Carcinogenic Risk[S]. (2013 -02). [2014 -03 -31]. http://www, ieh. org/ product s/guidelines/multi-disciplinary / article/muhidisciplinary- guidelines, html.
  • 8ARIENS E.I. Domestication of chemistry by design of safer chemi- cals: structure-activity relationships[J]. Drug Metab Rev, 1984, 15 ( 3 ) :425 - 504.
  • 9WEISBURGER JH. Environmental Health Perspectives [ J] 1983, 50: 233-245.
  • 10WOO YT. Quantitative Structure-Activity Relationship (QSAR) models of mutagens and carcinogens [ M]. CRC Press: Boca Ra- ton, 2003 : Chapter 2.

共引文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部